|
|
|
| Clinical efficacy of mifepristone combined with Gongliuxiao capsule for treating women with uterine leiomyoma |
| Boai Hospital, Zhongshan city, Guangdong Province, 528403 |
|
|
|
Abstract To investigate the clinical efficacy of mifepristone combined with Gongliuxiao capsule for treating women with uterine leiomyoma. Methods: From March 2017 to January 2019, 92 women with uterine leiomyoma were selected and randomly divided into 30 cases in group A, 30 cases in group B, and 32 cases in group C. The women in group A were treated with mifepristone, women in group B were treated with Gongliuxiao capsule, and women in the group C were treated with mifepristone combined with Gongliuxiao capsule. The clinical effect, the changes of uterine volume and tumor volume, and the level of sex hormone (estrogen (E2), serum follicle stimulating hormone (FSH), progesterone (P) and luteinizing hormone (LH) before and after treatment, and adverse reactions and recurrence rates were observed among the three groups. Results: After treatment, the total effective rate of women in group C was 93.7%, which was significant higher than that (73.3%) of women in group A and that (70.0%) of women in group B (P<0.05). After treatment, the volume of uterus and leiomyoma of women in the three groups had reduced significantly, and those of women in group C were significant smaller than those of women in group A and B. And the levels of E2, FSH, P, LH and other sex hormones of women in the three groups had decreased significantly, and those of women in group C were significant lower than those of women in group A and B (all P<0.05). The incidence of adverse reactions of women in group C was 3.1%, which was significant lower than that (26.7%) of women in group A and that (16.7%) of women in group B, and the recurrence rate of women in group C was 6.3%, which was significant lower than that (23.3%) of women in group A and that (26.7%) of women in group B (all P<0.05). Conclusion: Mifepristone combined with Gongliuxiao capsule for treating women with uterine leiomyoma has better clinical efficacy, which can significantly reduce the volumes of uterus and leiomyoma, and can decrease the levels of sex hormones, adverse reaction, and recurrence rate.
|
|
|
|
|
|
|
|
|
